The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-02-01 / Neurosurg Focus 2021 02;50(2):E8Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Antitumor Activity of Curcumin in Glioblastoma
/in Curcuma, Glioblastoma, International Publications /von 2020-12-11 / Int J Mol Sci 2020 Dec;21(24)Hyperthermia treatment advances for brain tumors
/in Glioblastoma, Hyperthermia, International Publications /von 2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-19Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-303Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2020-06-05 / Cells 2020 Jun;9(6)Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-05-13 / Hum Vaccin Immunother 2020 May;:1-9Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-01-16 / NPJ Vaccines 2020;5:5
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de